

# Parkinson's Disease - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P87158B393FEN.html>

Date: April 2020

Pages: 1201

Price: US\$ 2,500.00 (Single User License)

ID: P87158B393FEN

## Abstracts

Parkinson's Disease - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H1 2020, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 47, 58, 4, 212, 90 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 51 and 15 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Parkinson's Disease - Overview

Parkinson's Disease - Therapeutics Development

Parkinson's Disease - Therapeutics Assessment

Parkinson's Disease - Companies Involved in Therapeutics Development

Parkinson's Disease - Drug Profiles

Parkinson's Disease - Dormant Projects

Parkinson's Disease - Discontinued Products

Parkinson's Disease - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Parkinson's Disease, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),  
H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2),  
H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3),  
H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Parkinson's Disease, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

1st Bio Therapeutics Inc  
4D Pharma Plc  
Abaxy Sprl  
AbbVie Inc  
Abivax SA  
ABL Bio Inc  
AC Immune SA  
Acelot Inc  
AcuraStem Inc  
Addex Therapeutics Ltd  
Affichem SA  
AFFiRiS AG  
AgoneX Biopharmaceuticals Inc  
Alan Laboratories Inc  
Alector Inc  
Alectos Therapeutics  
Alexza Pharmaceuticals Inc  
Alkahest Inc  
Alkermes Plc  
Allife Medical Science and Technology Co Ltd  
AlphaCognition Inc

Alsonex Pty Ltd  
Alterity Therapeutics Ltd  
Amabiotics SAS  
Amathus Therapeutics Inc  
Amneal Pharmaceuticals Inc  
Anavex Life Sciences Corp  
Anida Pharma Inc  
Annovis Bio Inc  
Antoxis Ltd  
Aoxing Pharmaceutical Company Inc  
Apollo Therapeutics LLC  
Appello Pharmaceuticals Inc  
Aprinoia Therapeutics Inc  
AptaBio Therapeutics Inc  
Aptamer Sciences Inc  
Araclon Biotech SL  
Aranda Pharma Ltd  
AriBio  
ArmaGen Inc  
Arrien Pharmaceuticals LLC  
Arvinas Inc  
Asdera LLC  
Asklepios BioPharmaceutical Inc  
Aspen Neuroscience Inc  
Astellas Pharma Inc  
AstraZeneca Plc  
Athersys Inc  
Athira Pharma Inc  
Auritec Pharmaceuticals Inc  
Avicanna Inc  
Axial Biotherapeutics Inc  
Axovant Gene Therapies Ltd  
AZTherapies Inc  
Azymus Therapeutics Inc  
B&A Therapeutics  
BCWorld Pharm Co Ltd  
Belrose Pharma Inc  
Berg LLC  
Better Life Pharmaceuticals Inc



Bial - Portela & Ca SA  
Bio-Modeling Systems SAS  
Bio-Pharm Solutions Co Ltd  
Bioasis Technologies Inc  
Biogen Inc  
BlueRock Therapeutics  
BrainStorm Cell Therapeutics Inc  
Bristol-Myers Squibb Co  
C4X Discovery Holdings Plc  
Calico LLC  
Califia Bio Inc  
Cantabio Pharmaceuticals Inc  
Canvax Biotech SL  
Capo Therapeutics Inc  
Carmot Therapeutics Inc  
Carna Biosciences Inc  
Cavion LLC  
CavoGene LifeSciences  
Celavie Biosciences LLC  
CellCure  
Cellivity Therapeutics Inc  
Cellix Bio Pvt Ltd  
Cerecin Inc  
Cerecor Inc  
CereSpir Inc  
Cerevance Inc  
Cerevel Therapeutics LLC  
CHA Biotech Co Ltd  
Chase Therapeutics Corp  
Chiesi Farmaceutici SpA  
Chipscreen Biosciences Ltd  
CholesteniX Ltd  
Chongqing Pharmaceutical Research Institute Co Ltd  
Ci Therapeutics  
Clayton Biotechnologies Inc  
Clene Nanomedicine Inc  
Clevexel Pharma SAS  
Cogentis Therapeutics Inc  
Collaborative Medicinal Development LLC

Contera Pharma ApS  
Copernicus Therapeutics Inc  
Corium, Inc.  
Crossject SA  
CuraSen Therapeutics Inc  
Curemark LLC  
CuroNZ Ltd  
Curyx Bio Inc  
Cypralis Ltd  
Dadang & BIO Co Ltd  
DanPET AB  
Declion Pharmaceuticals Inc  
DegenRx BV  
Denali Therapeutics Inc  
DermaXon LLC  
Diffusion Pharmaceuticals Inc  
Dina Pharmaceuticals Inc  
Dizlin Medical Design AB  
Domain Therapeutics SA  
DongKoo Bio & Pharma Co Ltd  
E-scape Bio Inc  
Easywell Biomedical Inc  
Eisai Co Ltd  
Eli Lilly and Co  
Emerald Health Sciences Inc  
Emerald Organic Products Inc  
Energenesis Biomedical Co Ltd  
Evgen Pharma Plc  
Fabre-Kramer Pharmaceuticals Inc  
Fortuna Fix Inc  
Fulcrum Therapeutics Inc  
GB Sciences Inc  
Generoath Co Ltd  
Genervon Biopharmaceuticals LLC  
GenKyoTex SA  
Genmab AS  
Genzyme Corp  
Gismo Therapeutics Inc  
Global BioLife Inc Ltd

GNT Pharma Co Ltd  
Grespo AB  
GT Gain Therapeutics SA  
Guangzhou Magpie Pharmaceutical Co Ltd  
H. Lundbeck AS  
Hebei Newtherapy Bio-Pharma Technology Co Ltd  
Herantis Pharma Plc  
HitGen LTD  
Hong Kong WD Pharmaceutical Co Ltd  
Hope Biosciences LLC  
Icagen Inc  
ICB International Inc  
Icure Pharmaceutical Inc  
Imago Pharmaceuticals Inc  
Immune Modulation Inc  
Immungenetics AG  
Impel NeuroPharma Inc  
Inexia Ltd  
Inflazome Ltd  
Inhibikase Therapeutics Inc  
InnoMedica Holding AG  
Intec Pharma Ltd  
International Stem Cell Corp  
Intra-Cellular Therapies Inc  
Invisio Ltd  
Io Therapeutics Inc  
Ionis Pharmaceuticals Inc  
IRLAB Therapeutics AB  
Jazz Pharmaceuticals Plc  
Jeil Pharmaceutical Co Ltd  
Junaxo Inc  
Kainos Medicine Inc  
Kariya Pharmaceuticals IVS  
Kashiv BioSciences LLC  
Keapstone Therapeutics Ltd  
Kissei Pharmaceutical Co Ltd  
Kyowa Kirin Co Ltd  
Lauren Sciences LLC  
Lead Discovery Center GmbH

Living Cell Technologies Ltd  
Longevity Biotech Inc  
Luye Pharma Group Ltd  
Lysosomal Therapeutics Inc  
Macrobian Biotech BV  
Mavalon Therapeutics Ltd  
MD Healthcare Inc  
Med-Life Discoveries LP  
MedGenesis Therapeutix Inc  
MeiraGTx Holdings Plc  
Merck & Co Inc  
Meta-IQ ApS  
Metabolic Solutions Development Company LLC  
MetiMedi Pharmaceuticals Co Ltd  
MetVital Inc  
MimeTech Srl  
Minerva Neurosciences Inc  
Mission Therapeutics Ltd  
Mitochon Pharmaceuticals Inc  
Mitoconix Bio Ltd  
MitoDys Therapeutics Ltd  
Mitokinin LLC  
Mitsubishi Tanabe Pharma Corp  
Modag GmbH  
Montisera Ltd  
Motac Neuroscience Ltd  
Neonc Technologies Inc  
Netherlands Translational Research Center BV  
NeuBase Therapeutics Inc  
NeuExcell Therapeutics Inc  
Neuracle Science Co Ltd  
Neuraly Inc  
Neuren Pharmaceuticals Ltd  
Neuro Vigor LLC  
Neurocea Pharmaceuticals  
Neurochlore  
Neurodon LLC  
Neuroene Therapeutics LLC  
NeuroGeneration Inc

Neurona Therapeutics Inc  
NeuroNascent Inc  
NeuroPn Therapeutics LLC  
Neuropore Therapies Inc  
Neurotrope Bioscience Inc  
New Amsterdam Sciences Inc  
New Biotic Inc  
New World Laboratories Inc  
Newron Pharmaceuticals SpA  
Nitrome Biosciences Inc  
nLife Therapeutics SL  
NLS Pharma Group  
Novartis AG  
Novo Nordisk AS  
NTZ Lab Ltd  
NutriBand Inc  
Omeros Corp  
Oncodesign SA  
Orphazyme A/S  
Orpheris Inc  
Oryzon Genomics SA  
Oxyrane Belgium NV  
Parkure Ltd  
Peptron Inc  
Pfizer Inc  
Pharma Two B Ltd  
Pharmatrophix Inc  
Pharmicell Co Ltd  
Phoenix Biotechnology Inc  
Phoenix Life Sciences International Ltd  
PK Biosciences Corp  
Plex Pharmaceuticals Inc  
Polaryx Therapeutics Inc  
PolyCore Therapeutics LLC  
Prevail Therapeutics Inc  
Priavoid GmbH  
Primary Peptides Inc  
Proclara Biosciences Inc  
ProMIS Neurosciences Inc

Promius Pharma LLC  
Prothena Corp Plc  
Prous Institute for Biomedical Research SA  
Psy Therapeutics Inc  
PTC Therapeutics Inc  
reMYND NV  
Renown Pharmaceuticals Pvt Ltd  
resTORbio Inc  
Retrotope Inc  
Revalesio Corp  
Rich Pharmaceuticals Inc  
Rionis LLC  
Sage Therapeutics Inc  
SalubRx Therapeutics Inc  
SanBio Inc  
Sandoz International GmbH  
Saniona AB  
Sanofi  
Seelos Therapeutics, Inc.  
Seneb BioSciences Inc  
Sengenics International Pte Ltd  
Serina Therapeutics Inc  
Shanghai Angecon Biotechnology Corp  
Shenox Pharmaceuticals LLC  
Shift Bioscience Ltd  
SignPath Pharma Inc  
Sinfonia Biotherapeutics Inc  
Sorrento Therapeutics Inc  
SparkBioPharma Inc  
STATegics Inc  
Sumitomo Dainippon Pharma Co Ltd  
Sun Pharma Advanced Research Company Ltd  
Sunovion Pharmaceuticals Inc  
Suven Life Sciences Ltd  
Synthonics Inc  
Takeda Pharmaceutical Co Ltd  
Tarus Therapeutics Inc  
TauRx Therapeutics Ltd  
Techfields Pharma Co Ltd

TechnoPhage SA  
Teikoku Pharma USA Inc  
Tranquis Therapeutics Inc  
TreeFrog Therapeutics SAS  
Treventis Corp  
Trucode Gene Repair Inc  
UCB SA  
UniQure NV  
United Neuroscience Ltd  
Varinel Inc  
Verge Genomics Inc  
Videns Incorp Ltd  
Vivreon Biosciences LLC  
Voyager Therapeutics Inc  
WhanIn Pharmaceutical Co Ltd  
Xcelthera INC  
Xoc Pharmaceuticals Inc  
XYnapse Therapeutics Pty Ltd  
Yuhan Corp  
Yumanity Therapeutics  
Zhitty Genesis Medicine Inc

## I would like to order

Product name: Parkinson's Disease - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P87158B393FEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P87158B393FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970